Notable Quotes
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk High: | ||
Experts Commenting on This Company
|
* |
Johnson & JohnsonTICKER: JNJ:NYSEJohnson & Johnson has built the most comprehensive base of healthcare businesses in the world, generating approximately 70% of its revenues from its number one or number two global leadership positions in its respective markets. Its consumer products, pharmaceuticals, medical devices and diagnostics play a role in helping millions of people be well and stay well every day. The company remains committed to improving the health and well-being of people everywhere, profitably growing its businesses and enhancing the value it can bring to its shareholders. |
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Stephen O'Neil, Hilliard Lyons (4/17/13) " Double-digit growth in two segments contributed to higher Q1 sales for Johnson & Johnson. . .U.S. sales rose 11% with growth in pharmaceuticals and medical devices. . .new drugs performed well. . .in particular, the biologic Stelara, Incivo for hepatitis C, the cancer drug Zytiga, and the anticoagulant Xarelto achieved strong sales growth. . .we view the company's diverse business mix positively. Strong finances allow for share repurchases, opportunistic acquisitions and dividend growth."
Trefis (4/3/13) "Johnson & Johnson has received a major boost as its blockbuster potential type 2 diabetes drug, Invokana (commonly known as canagliflozin), was granted U.S. Food and Drug Administration approval. The approval marks the company's first entry into the huge diabetes market. . .we currently expect the drug to achieve over $1B in peak sales."
Trefis (3/6/13) "Johnson & Johnson's blockbuster potential experimental drug, canagliflozin, is expected to receive U.S. Food and Drug Administration approval by the end of the month. . .while the potential of the drug is much higher, currently we expect the drug to achieve over $1B in expected peak sales."
Larry Biegelsen, Wells Fargo Securities (3/1/13) "Johnson & Johnson finished 2012 on a strong note in terms of its pharma pipeline. . .pending pharmaceutical pipeline events in H1/13 include canagliflozin for diabetes PDUFA date around end of March, PDUFA date for Xarelto for acute coronary syndrome indication is around March 7, U.S. and European simeprevir for Hepatitus C regulatory filings in H1/13. . .we believe the company's business is starting to turn the corner and we expect the pipeline to deliver accelerating growth."
Rajeev Jashnani, UBS Securities (2/21/13) "Johnson & Johnson has two key opportunities on the horizon with canagliflozin and Xarelto acute coronary syndrome. . .the Street is probably baking in <$500M whereas the upside case could add $2.5B in revenues (adding ~1% to our 2013–2016 revenue compound annual growth rate of ~4%) and 6% to earnings per share by 2016."
Johnson & Johnson Content
The Life Sciences Report